Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

已完结 10 由 karry 发布于 2026/6/29 14:14:03

DOI:10.1016/s1470-2045(24)00636-3
作者：Dan-Yun Ruan, Fu-Rong Liu, Xiao-Li Wei, Su-Xia Luo, Zhi-Xiang Zhuang, Zhen-Ning Wang, Fu-Nan Liu, Yan-Qiao Zhang, Jian-Wei Yang, Zhen-Dong Chen, Yong-Sheng Wang, Jun-Ye Wang, Xiao-Hua Liang, Xiao-Jie
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundCMG901 is a novel first-in-class antibody–drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to asse

应助信息

7小时前

Book学术机器人

0953a927e9e311f08c8434735aa3bc31.pdf 已采纳

7小时前

Book学术机器人

2026/6/29 14:14:03 Book学术AI机器人已找到文献并上传

2026/6/29 14:14:03 Book学术AI机器人收到请求，开始寻找文献

2026/6/29 14:14:03 已向机器人发送请求

7小时前

karry 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库中药调控NF-κB信号通路治疗葡萄膜炎的研究进展